LANTHEUS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.6 USD | +2.80% |
|
+14.53% | +96.15% |
| Jul. 17 | Lantheus Holdings Insider Sold Shares Worth $266,417, According to a Recent SEC Filing | MT |
| Jul. 16 | Indices: What's small becomes cute again |  |
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.
Calendar
2024-07-31
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
121.6
USD
Average target price
135.5
USD
Spread / Average Target
+11.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +96.15% | 8.43B | |
| -6.51% | 12.14B | |
| -18.38% | 6.91B | |
| +9.07% | 5.93B | |
| -21.66% | 3.57B | |
| +5.36% | 2.53B | |
| +41.54% | 2.45B | |
| +17.41% | 2.94B | |
| -18.43% | 1.59B | |
| -9.77% | 1.38B |
- Stock Market
- Equities
- LNTH Stock
- News Lantheus Holdings, Inc.
- Lantheus Holdings Insider Sold Shares Worth $266,417, According to a Recent SEC Filing
